PharmaShots | Incisive News in 3 Shots

Subscribe Now

Regeneron

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

November 6, 2024

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

October 4, 2024

Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

September 30, 2024

PharmaShots Weekly Snapshots (September 23 – September 27, 2024)

PharmaShots Weekly Snapshots (September 23 – September 27, 2024)

September 27, 2024

Sanofi and Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Eosinophilic Esophagitis (EoE) in Children

Sanofi and Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Eosinophilic Esophagitis (EoE) in Children

September 23, 2024

Sanofi and Regeneron’s Dupixent Receives the US FDA’s Approval to Treat Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sanofi and Regeneron’s Dupixent Receives the US FDA’s Approval to Treat Adolescents with Chronic Rhinosinusitis with Nasal Polyps...

September 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us